Chemistree Technology’s (CHM.C) investee life-science company involved in pharma-grade natural health products, ImmunoFlex, received the Health Canada nod earlier this week for their FLEX 10 product, according to a press release.
FLEX 10 is ImmunoFlex’s N-Acetyl-L-cysteine health supplement formulation. It’s loaded with antioxidants. It comes in packs of thirty 600 mg capsules packaged in aluminum blisters to avoid unnecessary exposure to oxygen which would reduce their effectiveness.
“At ImmunoFlex, we work with the immune system to strengthen, support, and enhance our body’s natural surveillance and response system. FLEX 10 is the first product in our line up of products designed to achieve this goal so we could not be more delighted with the Health Canada approval,” said Chris Wagner, ImmunoFlex CEO.
Chemistree Technology themselves are an investment company with interests in the United States cannabis sector, real estate and biotech sectors. Their present strategy is to focus on investments with the strongest opportunities across a broad range of industries with an eye towards investing in early stage, promising companies where it can take a leading role and potentially provide investees with advisory services, mentoring and access to the company’s management expertise.
Chemistree Technologies dropped 14.3% today and is now trading at $0.15.